Intel shares reversed a rally to $126 on October 2, closing at $119.33, just $0.37 above the session low. The stock underperformed the broader technology benchmark RSPT over the past week, and traders are now watching whether support near $117–$118 holds or a deeper slide toward $110–$112.50 develops.
Intel touched $126 on October 2 before fading to close at $119.33, finishing just $0.37 above the session low of $118.96. The stock had rebounded from a September 29 low of $113.97, but Friday's reversal gave back most of that advance before the close.
Intel lags as the tech benchmark climbs
The retreat stands out because the broader technology sector kept rising. From September 24 to October 2, Intel fell 6.33% while the RSPT benchmark gained 3.40%, a gap of 9.73 percentage points. On October 2 alone, Intel declined 0.56% against a 1.04% advance for RSPT.
That divergence follows a sharp run higher. Between September 15 and September 24, Intel rose 31.14% versus 3.33% for RSPT, outperforming by 27.81 percentage points. The comparison does not identify who sold Intel shares or establish a cause, since RSPT is not a semiconductor-specific benchmark.
Earnings growth hasn't translated into a steady share price
Intel's stock path has been volatile since its last earnings report. According to Intel's second-quarter release published July 23, revenue rose 25% year over year to $16.1 billion. Yet Intel closed July 24 at $92.32, down 7.89% from its pre-results close of $100.23, and it fell further to $81.88 by July 29.
A September rally then pushed Intel to a $127.39 close on September 24, before the recent pullback erased much of that gain.
Support and resistance levels now in focus
Traders are watching $120–$122 as the first recovery hurdle, with $125–$127.50 as the main overhead test. Separately, a volume-profile reading from Intel's previous earnings quarter places an overhead decision zone at $128.75–$130.75, described as the prior quarter's value-area-high zone. On the downside, $117–$118 is the first support to watch, followed by $114–$116 and then $110–$112.50 if the decline deepens.
For existing shareholders, a sustained loss of $114–$116 would offer stronger technical evidence that the recovery is deteriorating, though it would not by itself change the underlying business outlook. A successful defense of support followed by a recovery above $120–$122 would weaken the case for selling on Friday's reversal alone.
Source: investingLive
Trading involves risk.
Risk Disclaimer
